Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Receivables (2024 - 2025)

Kura Oncology (KURA) has disclosed Receivables for 2 consecutive years, with $8.8 million as the latest value for Q4 2025.

  • Quarterly Receivables rose 327.38% to $8.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.8 million through Dec 2025, up 327.38% year-over-year, with the annual reading at $8.8 million for FY2025, 327.38% up from the prior year.
  • Receivables for Q4 2025 was $8.8 million at Kura Oncology, down from $35.9 million in the prior quarter.
  • The five-year high for Receivables was $48.7 million in Q1 2025, with the low at $2.1 million in Q4 2024.